Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. sums up a very successful #SABCS24: -Phase 2 EVANGELINE PK Run-In Study: Primary endpoint achieved; (Z)-endoxifen safe and well-tolerated -Phase 2 KARISMA-Endoxifen Study: Statistically significant (p<0.01) reduction in breast density with 1mg and 2mg (Z)-endoxifen doses -New Molecules Identified: Synergistic with (Z)-endoxifen for the treatment of breast cancer Check out all of our announcements from this week's San Antonio Breast Cancer Symposium here - https://lnkd.in/eK3m5-iE $ATOS #breastcancer

The discovery of new, synergistic compounds that could potentially complement the cancer preventing and fighting mechanism of (Z)-endoxifen showcases our continuing mission to transform the breast cancer paradigm. I congratulate our research team and collaborators on these discoveries as we continue to enlist advanced techniques to bring novel compounds and combinations with significant anti-cancer properties to the treatment of these challenging cancers. https://lnkd.in/gG-DZ-Hf

Our final presentation at #SABCS24 - Atossa Therapeutics, Inc. to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium -#BreastCancer https://lnkd.in/gC269huC

The top regional #healthcare and #biotech news for December 11th via the Big4Bio newsletters: San Diego: AnaptysBio's Mid-Stage Failure; Iambic Therapeutics Names CSO; More on Cardiff Oncology https://lnkd.in/gMvC6jS8 SF Bay: Exec Hires; Alveo Technologies, CareDx, Inc. Strike Deals; The Bio Report Podcast https://lnkd.in/gEKpNTGy Seattle: Allen Institute Leadership Change; Atossa Therapeutics, Inc. Endoxifen's Phase 2 Success; Hot Investor Profiles https://lnkd.in/g7hnN7-E Los Angeles: Angitia Biopharmaceuticals Secures $120M; ACELYRIN, INC.'s Phase 2b/3 Uveitis Treatment Insights; Arrowhead Pharmaceuticals' Clinical Progress https://lnkd.in/g5r93fZP Boston: nChroma Bio Forms; uniQure Stock Doubles; Compass Therapeutics Inc. Hires CFO; Syncell Inc Raises $15M https://lnkd.in/gp4HyZGn Philadelphia: The Wistar Institute Wins Two Grants; Orphan Tag for Pilatus Biosciences; More on Carisma Therapeutics https://lnkd.in/gzWDwjvn Capital Region: Novavax Branches Out; Protaryx Medical Completes First-in-Human Study; TransThera | 药捷安康 Shows Results https://lnkd.in/gchY5auY NYC: Kashiv BioSciences LLC Hires Execs; Cellectar Biosciences, Inc. Lays Off 60%; Hepion Pharmaceuticals, Pharma Two B Call It Quits; Negev Labs Launches https://lnkd.in/gT-evJy3

Atossa Therapeutics, Inc. Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density - #BreastCancer #BreastDensity #CancerPrevention #SABCS24 Read the full release here: https://lnkd.in/e56m38pt

More from today's announcement from CEO, Dr. Steven Quay - Atossa Therapeutics, Inc. presenting pharmacokinetic and tolerability data from our Ph2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium #SABCS24 #BreastCancer #ClinicalTrials $ATOS - https://lnkd.in/emu_2ZhM

Atossa Therapeutics, Inc. to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium #SABCS24 #BreastCancer #ClinicalTrials $ATOS https://lnkd.in/emu_2ZhM

Atossa Therapeutics, Inc. Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at #AACR Special Conference in #CancerResearch $ATOS https://lnkd.in/ei-bwiCA

For a refresher on our announcement from last month - which reported significantly reduced mammographic #BreastDensity, potentially paving the way for #innovative #CancerPrevention Strategies $ATOS - Check out the video explainer here https://lnkd.in/e_krQySS

Atossa Therapeutics, Inc. to Present Poster on (Z)-Endoxifen at #AACR Special Conference in Cancer Research #breastcancer #research #innovation $ATOS https://lnkd.in/epQ9BUV4